Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kura Oncology (KURA)

Kura Oncology (KURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,039,865
  • Shares Outstanding, K 87,018
  • Annual Sales, $ 53,880 K
  • Annual Income, $ -173,980 K
  • EBIT $ -294 M
  • EBITDA $ -306 M
  • 60-Month Beta 0.21
  • Price/Sales 19.35
  • Price/Cash Flow N/A
  • Price/Book 4.29

Options Overview Details

View History
  • Implied Volatility 145.76% (+11.43%)
  • Historical Volatility 63.58%
  • IV Percentile 79%
  • IV Rank 49.93%
  • IV High 245.33% on 04/07/25
  • IV Low 46.49% on 12/16/24
  • Expected Move (DTE 13) 1.29 (10.81%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 924
  • Volume Avg (30-Day) 1,459
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 29,985
  • Open Int (30-Day) 30,063
  • Expected Range 10.66 to 13.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.20
  • Number of Estimates 6
  • High Estimate 1.10
  • Low Estimate -0.48
  • Prior Year -0.22
  • Growth Rate Est. (year over year) +190.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.45 +26.43%
on 11/07/25
12.49 -4.32%
on 11/14/25
+2.01 (+20.22%)
since 11/05/25
3-Month
7.88 +51.65%
on 09/09/25
12.49 -4.32%
on 11/14/25
+3.73 (+45.38%)
since 09/05/25
52-Week
5.41 +120.89%
on 04/07/25
12.49 -4.32%
on 11/14/25
+1.24 (+11.58%)
since 12/05/24

Most Recent Stories

More News
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...

KURA : 11.95 (-0.25%)
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...

KURA : 11.95 (-0.25%)
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

SAN DIEGO and TOKYO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced KOMZIFTI™ (ziftomenib),...

KURA : 11.95 (-0.25%)
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

– NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R NPM1 -mutated AML defined by historically poor outcomes and low...

KURA : 11.95 (-0.25%)
Kura Oncology to Participate in Upcoming Investor Conference

SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 11.95 (-0.25%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...

KURA : 11.95 (-0.25%)
Kura Oncology: Q3 Earnings Snapshot

Kura Oncology: Q3 Earnings Snapshot

KURA : 11.95 (-0.25%)
Kura Oncology Reports Third Quarter 2025 Financial Results

– New Drug Application for ziftomenib in adults with R/R NPM1 -m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 – – KOMET 017 Phase 3 trials to evaluate...

KURA : 11.95 (-0.25%)
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 11.95 (-0.25%)
Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting

– Data to be featured in two oral presentations on December 8, 2025 – – Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate...

KURA : 11.95 (-0.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL,...

See More

Key Turning Points

3rd Resistance Point 12.66
2nd Resistance Point 12.40
1st Resistance Point 12.17
Last Price 11.95
1st Support Level 11.68
2nd Support Level 11.42
3rd Support Level 11.19

See More

52-Week High 12.49
Last Price 11.95
Fibonacci 61.8% 9.79
Fibonacci 50% 8.95
Fibonacci 38.2% 8.11
52-Week Low 5.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar